" Psoriasis" . . . " UV-B" . . "Zhodnocen\u00ED \u00FArovn\u011B zdravotn\u00EDho rizika Goeckermanovy terapie (UV-B + dehet) psori\u00E1zy u dosp\u011Bl\u00FDch." . " Coal tar" . . . "Health risk level evaluation of Goeckerman`s therapy (UV-B and coal tar) of psoriasis in adults"@en . "NR8154" . . . "1"^^ . "Health risk; Coal tar; PAU; UV-B; Goeckerman`s method; Psoriasis; Immunotoxicity; Genotoxicity"@en . . "0"^^ . . "Goeckerman\u015B therapy of psoriasis. Exposure to coal tar, PAHs and UV radiation. Significant therapeutic effect, significant immunosuppressive effect, increased carcinogenic risk. Statification of coal tar by individual carcinogenic risk is possible."@en . "0"^^ . . . . " Immunotoxicity" . " PAU" . . . "http://www.isvav.cz/projectDetail.do?rowId=NR8154"^^ . " Goeckerman`s method" . "PAU and UV-B represent mutagenic (carcinogenic) and immunotoxic environmental agents. Incidence of psoriasis is growing. Goeckerman`s therapy of psoriasis (GT) exposes patients to combined effect PAH and UV-B (often used as method of first option). GT develops conditions for health risk generation that, until now, has not been methodically evaluated and quantified. Project is focused on methodic evaluation and quantification of genotoxic and immunotoxic risk of GT. Exposure monitoring, biological monitoring and procedure of health risk assessment will be used in methods. Hospitalized adults with psoriasis, cured by GT, will be observed. Each patient will be as a control to himself. Recommendation of extent, duration and frequency of GT with acceptable health risk will be major result. Benefit of the project consists in reduction of uncertainties and doubts from adverse effects of GT (medical-juridical and socio-economic aspects)."@en . . . "12"^^ . . "12"^^ . "Goeckermanova terapie psori\u00E1zy. Kamouheln\u00FD dehet, PAU a UV z\u00E1\u0159en\u00ED. V\u00FDznamn\u00FD terapeutick\u00FD efekt, v\u00FDznamn\u00FD imunosupresivn\u00ED efekt a zv\u00FD\u0161en\u00E9 karcinogenn\u00ED riziko. Stratifikace individu\u00E1ln\u00EDho karcinogenn\u00EDho rizika dehtu je mo\u017En\u00E1."@cs . . . "Health risk" . "Polycyklick\u00E9 aromatick\u00E9 \u00FAhlovod\u00EDky (PAU) a UV-B reprezentuj\u00ED mutagenn\u00ED (karcinogenn\u00ED) a imunotoxick\u00E1 evironment\u00E1ln\u00ED agens. V\u00FDskyt psori\u00E1zy stoup\u00E1. Geckermanova terapie psori\u00E1zy (GT) vystavuje \u010Dlov\u011Bka kombinovan\u00E9 expozici PAU a UV-B (\u010Dasto metoda volby). GT vytv\u00E1\u0159\u00ED podm\u00EDnky pro vznik zdravotn\u00EDho rizika, kter\u00E9 dosud nebylo metodicky hodnoceno a kvantifikov\u00E1no. Projekt je zam\u011B\u0159en na metodick\u00E9 zhodnocen\u00ED a kvantifikaci genotoxick\u00E9ho a imunotoxick\u00E9ho rizika GT. Metodicky budou vyu\u017Eity prost\u0159edky monitorov\u00E1n\u00ED expozice, biologick\u00E9ho monitorov\u00E1n\u00ED expozice a \u00FA\u010Dinku a prost\u0159edky procedury hodnocen\u00ED zdravotn\u00EDch rizik. Sledov\u00E1ni budou dosp\u011Bl\u00ED pacienti s psori\u00E1zou, l\u00E9\u010Den\u00ED GT. Ka\u017Ed\u00FD pacient je kontrolou s\u00E1m sob\u011B. Hlavn\u00EDm v\u00FDsledkem bude doporu\u010Den\u00ED rozsahu, trv\u00E1n\u00ED a opakov\u00E1n\u00ED GT s p\u0159ijatelnou \u00FArovn\u00ED rizika. P\u0159\u00EDnos projektu spo\u010D\u00EDv\u00E1 v redukci vysok\u00E9 m\u00EDry nejistoty a obav pacient\u016F i l\u00E9ka\u0159\u016F z vedlej\u0161\u00EDch \u00FA\u010Dink\u016F GM (aspekty medic\u00EDnsko-pr\u00E1vn\u00ED a socio-ekonomick\u00E9)." . "2007-08-08+02:00"^^ . . .